For instance, the use of trichostatin, a pan-HDAC inhibitor, or of HDAC class I-specific inhibitors, like mocetinostat and PD-106, have been shown to be effective against cardiac fibrosis in various animal models of MI and hypertension, ameliorating heart function [102,103,104]. This evidence concerns the gene HDAC9 and hypertensive disorder.